Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)

Trial Profile

A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idronoxil (Primary)
  • Indications COVID 2019 infections; Multiple organ failure; SARS-CoV-2 acute respiratory disease; SARS-CoV-2 sepsis; Septic shock
  • Focus Adverse reactions
  • Acronyms NOXCOVID; NOXCOVID-1
  • Sponsors Noxopharm
  • Most Recent Events

    • 25 Aug 2021 According to a Noxopharm media release, based on initial positive results from this trial, company has started discussions to add Veyonda to one of the global clinical trial programs looking at identifying effective anti-inflammatory therapies in COVID-19 disease.
    • 25 Aug 2021 Results presented in a Noxopharm Media Release.
    • 24 Aug 2021 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top